Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × NSCLC × Erlotinib Hydrochloride × Clear all

Phase

Phase NA 1 Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 42 Lung Neoplasms 10 Pancreatic Neoplasms 5 Non-Squamous Non-Small Cell Lung Cancer 5 Neoplasms 3 Colorectal Neoplasms 3 Neoplasm Metastasis 2 Carcinoma 2 Brain Neoplasms 2 Thoracic Neoplasms 1 Stage IV EGFR Mutated Non-Small Cell Lung Cancer 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Rectal Neoplasms 1 Pancreatic Intraductal Neoplasms 1 Ovarian Neoplasms 1 Non-squamous Non-small Cell Lung Cancer 1 Non - Small Cell Lung Cancer NSCLC 1 Neoplasms by Site 1 NSCLC 1 Mouth Neoplasms 1 Lung Diseases 1 Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1 Head and Neck Neoplasms 1 Fallopian Tube Neoplasms 1 Esophageal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Large Cell 1

Interventions

osimertinib 3 Vinorelbine 3 Pemetrexed 3 Cisplatin 3 Carboplatin 3 Gemcitabine 2 Gefitinib 2 Docetaxel 2 CP protocol 2 rezivertinib 1 pembrolizumab 1 aumolertinib 1 Taxes 1 Paclitaxel 1 HMPL-013 1 HM781-36B 1 Erlotinib Hydrochloride 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02140333 2015-02-12

Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC

The First Affiliated Hospital of Guangzhou Medical University

Phase 3 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡